VivoSeq
Infectious Disease

Respiratory Syncytial Virus (RSV)

2

Pipeline Programs↗

13

Active Trials↗

14

Companies Involved↗

Respiratory Syncytial Virus (RSV) is an early-stage landscape with 2 programs across 14 companies. The most active players are Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Pfizer, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

2 programs

Phase 1Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

PreclinicalGSK logo

GSK

0 programs

PreclinicalModerna logo

Moderna

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Palivizumab /kg

AstraZeneca

Phase 1
No programs
Phase 2
No programs
Phase 31

Rsvpref

Pfizer

Approved
No programs

Analysis

Trial Status

63

clinical trials

Completed40 · 63%
Active, not recruiting8 · 13%
Terminated6 · 10%
Not yet recruiting4 · 6%
Unknown status2 · 3%
Withdrawn2 · 3%
Other1 · 2%

Clinical Trials

Trial Activity

63 trials

A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT06851806·138 enrolled
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
Active, not recruiting·Moderna logoModerna·Phase 3·NCT07117487·507 enrolled
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Active, not recruiting·GSK logoGSK·Phase 3·NCT04732871·1,720 enrolled
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
Active, not recruiting·Sanofi logoSanofi·Phase 4·NCT07109297·110 enrolled
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
Active, not recruiting·GGuangzhou Patronus Biotech Co., Ltd.·Phase 1·NCT06904222·90 enrolled
STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)
Active, not recruiting·Pfizer logoPfizer·N/A·NCT07122661·1 enrolled
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
Active, not recruiting·Pfizer logoPfizer·N/A·NCT06813872·1 enrolled
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
Active, not recruiting·Moderna logoModerna·Phase 3·NCT06067230·1,153 enrolled
A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease
Active, not recruiting·Pfizer logoPfizer·N/A·NCT06077968·1 enrolled
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
Not yet recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 1·NCT07492706·120 enrolled
A Phase 1, Randomized, Double-Blind, Ascending-Dose Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection in Healthy Adult Participants
Not yet recruiting·BBeijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07694557·180 enrolled
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
Not yet recruiting·Pfizer logoPfizer·Phase 3·NCT07653100·540 enrolled
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
Not yet recruiting·Pfizer logoPfizer·N/A·NCT07673081·293,334 enrolled
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
Completed·NNovavax·Phase 1·NCT01290419·150 enrolled
A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT04068792·22 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)